of saphenous vein-derived smooth muscle cells with a temperature sensitive (ts) SV40 LT-antigen [Hsieh et al., Arterioscler Thromb Vasc Biol 2000; 20:973-81.] . Although transformed, these cells retain a number of cytoskeletal characteristics typical of smooth muscle, particularly when cultured at a non-permissive temperature (39°C) that inhibits expression of LT-antigen. The object of these studies was to examine the reponses to agonists in this cell line. Increases in intracellular Ca 2ϩ ([Ca 2ϩ ] i ) in response to agonists were measured in SM1 cells cultured in DMEM containing 15% FCS at 37°C or 39°C for 5-7 days. Prior to experiments cells were loaded with 5M fura-2AM for 1h. Cells were then washed, trypsinized and resuspended in modified Kreb[scquote]s buffer. [Ca 2ϩ ] i was measured as previously described [Hughes & Schachter, Cell Calcium 1994; 15:317-330.] . Unstimulated levels of [Ca 2ϩ ] i were 90Ϯ7nM (nϭ30) and 97Ϯ8nM (nϭ24) at 37°C and 39°C respectively. Increases in [Ca 2ϩ ] i (nM) in response to stimuli are shown (Table) . Following exposure to 39°C responses to platelet-derived growth factor-BB (PDGF; 10ng/ml), epidermal growth factor (EGF; 100ng/ml) phenylephrine (PE; 10M), angiotensin II (AII; 1M) and endothelin (ET-1; 100nM) were increased. The response to bradykinin (BK; 100nM) did not change significantly. Phospholipase C (PLC) plays an important role in cellular signalling. A number of isoforms of PLC exist; PLC␥1 is highly expressed in fetal and neoplastic tissue, while PLC␦1 is present in large amounts in differentiated smooth muscle. The objective of these studies was to examine the effect of conditions affecting differentiation state on patterns of PLC isoform expression in human vascular smooth muscle cells. Human saphenous vein derived smooth muscle cells (HVSMC) were cultured in DMEM containing 15% foetal calf serum. Smooth muscle ␣-actin (SM ␣-actin) and PLC isoforms were determined in cell lysates derived from HVSMC (passage 3) by SDS PAGE and Western blotting. Only PLC␦1 and PLC␥1 were detectable in HVSMC, although PLC ␤1, ␤3, ␤4, ␦1, ␦2, ␥1, ␥2 were demonstrable in lysates from rat brain. The effect of changing differentiation state on the relative expression of PLC␦1 and PLC␥1 was investigated by serum withdrawal for seven days (SFM), exposure to retinoic acid (10M) for 72h or exposure to a HMG CoA reductase inhibitor, lovastatin (3M) for 24h. Western blots were analysed by densitometry. Data are meanϮSEM of the % change in protein estimated by densitometry with respect to untreated control HVSMC.
All three conditions significantly increased SM ␣-actin, a marker for a more differentiated state in smooth muscle. PLC␦1 levels increased, while PLC␥1 levels fell, in association with the increase in SM ␣-actin (Table) .
In conclusion, three different conditions that increase differentiation state of HVSMC had similar effects on PLC isoform expression. Changes in PLC␦1 and PLC␥1 were inversely related; an increase in PLC␦1 expression was associated with increased SM ␣-actin and increased differentiation state. These data suggest a possible role for changes in PLC␦1 and PLC␥1 expression in the regulation of differentiation state in HVSMC. Recent studies from this laboratory have shown that insulin rapidly inhibits thrombin-mediated Rho kinase activation and decreases myosin light chain (MLC20) phosphorylation and contraction in cultured primary vascular smooth muscle cells (VSMCs) by activating myosin-bound phosphatase(MBP). Because Rho kinase is one of the downstream targets of RhoA, we examined the effect of insulin on thrombin-mediated RhoA activation and its translocation to membrane fraction under the conditions where signaling via nitric oxide and cGMP pathways is prevented by pretreatment with L-NMMA (a nitric oxide synthase inhibitor) and RpcGMP (a cGMP antagonist) respectively. Incubation of confluent serum starved VSMCs with thrombin (1 U/ml)for 5 min caused a 2-3 fold increase in the content of RhoA in the membrane fraction which was blocked by preincubating VSMCs with 100 nM insulin for 10 min. In contrast, insulin failed to inhibit thrombin-mediated RhoA translocation in VSMCs isolated from spontaneous hypertensive rats. In control VSMCs, pretreatment with L-NMMA (1 mM)and RpcGMP (10 uM)for 60 min attenuated insulin's inhibitory effect on thrombin-mediated RhoA translocation and Rho kinase activation. In contrast, sodium nitroprusside (a nitric oxide donor) as well as 8-bromo-cGMP, a cGMP agonist mimicked insulin's inhibitory effects and prevented thrombin-mediated RhoA translocation. Furthermore, insulin caused a 2-fold increase in phosphorylation of RhoA which was blocked by Wortmaninn, a PI3-kinase inhibitor, L-NMMA, RpcGMP and 10 uM ODQ, a selective inhibitor of guanylate cyclase. Collectively, these results indicate that insulin phosphorylates and negatively modulates RhoA signaling via the PI3-kinase/NO/cGMP pathway to promote vosodilation by activating MBP which dephosphorylates MLC20.
Key Words: nitric oxide/cGMP, Rho kinase, Insulin/thrombin/hypertension In several cardiovascular diseases, vascular hypertrophy results, at least in part, from an abnormal proliferation of vascular smooth muscle cells (VSMCs). In vitro, calcium channel blockers (CCBs) have been reported to reduce VSMC proliferation by mechanisms distinct from their CCB activity but still unknown. We therefore investigated the mechanisms whereby amlodipine, a vasculo-selective CCB of the dihydropyridine series, could inhibit VSMC growth/proliferation induced by thrombin and basic fibroblast growth factor (bFGF). Experiments were carried out on cultured VSMCs isolated from human internal mammary artery or rat aorta. Ca 2ϩ movements and DNA synthesis were studied by measuring 171A AJH-April 2001-VOL. 14, NO. 4 , PART 2 POSTERS: Cell Biology/Growth Factors the intracellular Ca 2ϩ concentration in Fura2-labeled VSMCs and the incorporation of BrdU, respectively. Expression of c-myc, c-fos and c-jun proto-oncogenes was evaluated by semi-quantitative RT-PCR. The activation of p42/p44 mitogen-activated protein kinases (ERK 1/2) was evaluated by Western blots using an antibody against the activated form of ERK 1/2, i.e. phospho-ERK 1/2. Results demonstrated that amlodipine inhibited thrombin-induced Ca 2ϩ mobilization and its associated capacitative entry. These effects could not be observed with isradipine, verapamil or diltiazem. Amlodipine, like isradipine or nifedipine, inhibited bFGF-triggered voltage-dependent Ca 2ϩ influx and the resulting ERK 1/2 activation as well as thrombin-and bFGF-induced c-myc, c-fos and c-jun expression and DNA synthesis. The L-type Ca 2ϩ channel agonist Bay K 8644 could antagonize the inhibitory effect of nifedipine but not of amlodipine on DNA synthesis. Kinetic experiments indicated that the effect of amlodipine on Ca 2ϩ mobilization clearly dissociated from its effect on L-type Ca 2ϩ channels. All the effects of amlodipine were dose-dependent and could be observed with concentrations as low as 1-10 nM, i.e. concentrations that correspond to the peak plasma level of treated subjects. These data indicated that amlodipine exhibits specific properties, additional to its CCB activity, that affect Ca 2ϩ movements. Our results strongly suggest that it is by interfering with two branches of growth factor mitogenic pathways, namely Ca 2ϩ mobilization and ERK 1/2 activation, that amlodipine exerts its inhibitory activity on VSMC growth/proliferation. Amlodipine has also been reported to possess potent antioxidant and NO release activator properties. Along with these characteristics, the various properties of amlodipine reported in our investigations are likely to participate in amlodipine anti-atherogenic
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